Back

Healthcare utilisation and clinical outcomes following implementation of an accelerated treatment pathway for patients with HFrEF.

9 May 2026 (10:30 - 11:00)
Organised by: Logo
Congress Presentation Part of: Optimisation strategies in heart failure treatment Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Miss Melinda Copley

Auckland City Hospital, Auckland (New Zealand)

3 More presentations in this session

Presentation thumbnail
The prognostic role of regular NT-proBNP measurement after a rapid-up titration programme of guideline-directed medical therapy in heart failure: essential or superfluous?
Doctor B. Muk (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
The effect of increase in NT-proBNP on the efficacy and safety of a rapid up-titration of guideline-directed medical therapy in patients with low predischarge NT-proBNP
Doctor J. Papp (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Patient self-adjustment of diuretics in heart failure: evidence gaps despite guideline recommendations - insights from a scoping review
Ms E. O'Donoghue (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Optimisation strategies in heart failure treatment

The Event

Event poster

Heart Failure 2026

9 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Session
Advances in heart failure detection and therapy
thumbnail
Congress Session
Late breaking clinical trials: drugs and disease management
thumbnail
Congress Presentation
Rapid up-titration of guideline-directed medical therapy in real-world clinical practice: initial experience of a heart failure outpatient clinic

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources